NCT01995071 is a Phase 2 clinical trial of ABT-493 in Chronic Hepatitis C, sponsored by AbbVie.

Who is sponsoring NCT01995071?

NCT01995071 is sponsored by AbbVie.

What drugs are being tested in NCT01995071?

Interventions in NCT01995071: ABT-493, ABT-530, ABT-450/r/ABT-267, ABT-333, Ribavirin (RBV).

What condition does NCT01995071 study?

NCT01995071 studies Chronic Hepatitis C, Hepatitis C Virus, Compensated Cirrhosis.

Is NCT01995071 still recruiting?

NCT01995071 is currently completed. Last updated 8 July 2021.

Are results published for NCT01995071?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2021-07-08 · How we verify

NCT01995071

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Randomized, Open-Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-493 and ABT-530 in Adult Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

Completed Phase 2 Results posted Last updated 8 July 2021

What this trial tests

Phase 2 trial testing ABT-493 in Chronic Hepatitis C in 89 participants. Completed in 1 June 2015.

Timeline

1 November 2013

Primary endpoint
1 June 2015

1 June 2015

Quick facts

Lead sponsor	AbbVie
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	89
Start date	1 November 2013
Primary completion	1 June 2015
Estimated completion	1 June 2015

Drugs / interventions tested

ABT-493 — full drug profile →
ABT-530 — full drug profile →
ABT-450/r/ABT-267, ABT-333 — full drug profile →
Ribavirin (RBV) — full drug profile →

Conditions studied

Chronic Hepatitis C — all drugs for Chronic Hepatitis C →
Hepatitis C Virus — all drugs for Hepatitis C Virus →
Compensated Cirrhosis — all drugs for Compensated Cirrhosis →

Sponsor

AbbVie — full company profile →

Who can join

Adults 18 to 70, any sex, with Chronic Hepatitis C or Hepatitis C Virus. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Maximal Decrease From Baseline in log10 HCV RNA Levels During ABT-493 or ABT-530 Monotherapy Treatment
Time frame: Day 1 through prior to first dose of the combination regimen on Study Day 4
Maximal decrease from baseline in log10 HCV RNA levels during ABT-493 or ABT-530 monotherapy treatment. The baseline value was the last measurement before the first dose of monotherapy on Day 1.

Sponsor's own description

The purpose of this study is to evaluate the safety and antiviral effect of multiple doses of ABT-493 and ABT-530 in adults with genotype 1 HCV.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection.
Lawitz EJ, O'Riordan WD, Asatryan A, Freilich BL, et al · · 2015 · cited 34× · PMID 26711747 · DOI 10.1128/aac.02264-15
Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection.
Ng TI, Pilot-Matias T, Tripathi R, Schnell G, et al · · 2018 · cited 1× · PMID 30154359 · DOI 10.3390/v10090462

Verify or expand the search:

Other trials of ABT-493

Trials testing the same drug.

NCT02441283 — A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530 · Phase 2, PHASE3 · completed
NCT02243293 — A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and With · Phase 2, PHASE3 · completed

Other recruiting trials for Chronic Hepatitis C

Currently open trials in the same condition.

NCT06180590 — The Efficacy of Vosevi in Treating DAA-experienced Patients · recruiting
NCT03993925 — Enhancing Access to Care for Chronic Hepatitis C Infected Populations in Hong Kong · active not recruiting

Other AbbVie trials

Trials by the same sponsor.

NCT07219017 — A Study to Assess the Mass Balance of Oral ABBV-1354 in Healthy Adult Male Participants · Phase 1 · completed
NCT05316220 — A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years W · Phase 3 · withdrawn
NCT07024797 — Study to Assess the Adverse Events, Tolerability, and How Oral Doses of ABBV-932 Moves Through the Body in Healthy Adult · Phase 1 · completed
NCT07058051 — Cross-sectional Study to Characterize Real World Burden of Disease in Patients With Vitiligo in China · completed
NCT07007091 — A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administrations With a Pre-Filled · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01995071 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AbbVie
Last refreshed: 8 July 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01995071.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing